CAJ | 학술논문

目的:比较β-catenin在慢性髓性白血病(CML)各期中的表达情况,并分析与bcr/abl及伊马替尼细胞遗传学疗效的关系,为探讨CML疾病进展机制及寻找新的治疗靶点提供理论依据.方法:采用RT-PCR和Western blotting方法,检测99例CML患者骨髓单个核细胞中β-catenin mRNA和蛋白质水平的表达,分析与bcr/abl的相关性;94例CML患者服用伊马替尼1年后FISH检测bcr/abl融合基因,分析β-catenin与伊马替尼细胞遗传学疗效的关系.结果:CML急变期、加速期患者β-catenin的表达明显增高(P＜0.01),而慢性期与正常人无明显差别(P＞0.05);β-catenin与bcr/abl表达水平无明显相关性(r=0.314,P＞0.05);未达主要细胞遗传学缓解的CML患者β-catenin明显增高(P＜0.01).结论:CML疾病进展阶段β-catenin的表达明显升高,β-catenin的表达与bcr/abl无明显相关,而与伊马替尼疗效有关,β-catenin可能参与CML疾病进展机制,可作为新的治疗靶点.
목적:비교β-catenin재만성수성백혈병(CML)각기중적표체정황,병분석여bcr/abl급이마체니세포유전학료효적관계,위탐토CML질병진전궤제급심조신적치료파점제공이론의거.방법:채용RT-PCR화Western blotting방법,검측99례CML환자골수단개핵세포중β-catenin mRNA화단백질수평적표체,분석여bcr/abl적상관성;94례CML환자복용이마체니1년후FISH검측bcr/abl융합기인,분석β-catenin여이마체니세포유전학료효적관계.결과:CML급변기、가속기환자β-catenin적표체명현증고(P＜0.01),이만성기여정상인무명현차별(P＞0.05);β-catenin여bcr/abl표체수평무명현상관성(r=0.314,P＞0.05);미체주요세포유전학완해적CML환자β-catenin명현증고(P＜0.01).결론:CML질병진전계단β-catenin적표체명현승고,β-catenin적표체여bcr/abl무명현상관,이여이마체니료효유관,β-catenin가능삼여CML질병진전궤제,가작위신적치료파점.
AIM: To observe the expression of β-catenin in patients with chronic myeloid leukemia (CML) at different disease phases, and to analyze the relationship between BCR-ABL and cytogenetic response to imatinib mesylate. METHODS: RT-PCR and Western blotting were used to detect β-catenin mRNA and protein expression in bone marrow mononuclear cells (BMMNCs) from 99 patients with CML. The association with BCR-ABL and BCR-ABL fusion was determined by FISH in 94 patients after one year treatment with imatinib mesylate, and the relationship between β-catenin and cytogenetic response to imatinib mesylate was analyzed. RESULTS: The expression of β-catenin was increased significantly in patients with blast crisis and accelerated phase (P<0.01), while the expression of β-catenin between normal person and chronic phase of CML patients was not statistically different (P>0.05). No significant relation between β-catenin and BCR-ABL expression (r=0.314, P>0.05) was observed. The expression of β-catenin was increased significantly in the patients who did not reach main cytogenetic remission (P<0.01). CONCLUSION: The patients in progression phases of CML over-express β-catenin. The expression of β-catenin is not significantly related to BCR-ABL expression, but related to the therapeutic response of imatinib. Beta-catenin may be involved in the mechanism of CML progression and could be used as a new therapeutic target.